Connecticut Clinical Trials Report — June 2026

For Connecticut residents considering participation in clinical research, June 2026 presents a critical window of opportunity, particularly for trials nearing their conclusion. Across the state, 75 clinical trials are slated to close within the next 90 days, meaning time is running out to enroll. This includes 15 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

Individuals living with certain health conditions should also act quickly to explore trials with impending deadlines. Research focusing on various cancers, mental health, and substance use disorders are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Breast cancer (3 trials)
• Advanced solid tumor (3 trials)
• Opioid use disorder (2 trials)
• Major depressive disorder (2 trials)
• Triple negative breast cancer (2 trials)
• Alcohol use (2 trials)
• Advanced breast cancer (2 trials)
• AML (2 trials)
• Cannabis (2 trials)
• Healthy (2 trials)

New Research Horizons in Connecticut

This month, Connecticut welcomes 15 new clinical trials, offering fresh avenues for participation. While this is a slight decrease from the 19 trials that opened in May 2026, the new studies include several significant Phase 2 and Phase 3 drug trials from major pharmaceutical companies and leading academic institutions, providing access to cutting-edge treatments for widespread health challenges like migraine, obesity, and type 2 diabetes.

• Kallyope Inc. is sponsoring NCT07645924, a Phase 3 study evaluating "The Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine." This double-blind, randomized trial aims to enroll 1,800 participants to assess a new acute migraine treatment. Kallyope Inc. is also leading NCT07674654, a related Phase 3 "Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine," targeting 1,000 participants.
• For individuals living with obesity or overweight and type 2 diabetes, Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics, is sponsoring NCT07654374. This Phase 3 "Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)" plans for 1,100 participants to evaluate the long-term efficacy, safety, and tolerability of aleniglipron.
• AstraZeneca is also addressing type 2 diabetes with NCT07662044, a Phase 3 study investigating "The Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus." This trial seeks 800 participants.
• Eli Lilly and Company is leading an important pediatric study, NCT07668336, a Phase 3 "Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes." This research aims to enroll 170 participants aged 10 to less than 18 years.
• Individuals with migraine may also be interested in NCT07616128, a Phase 2 "Study of EVO756 in Adults With Migraine" sponsored by Evommune, Inc., targeting 330 participants.
• Boehringer Ingelheim is sponsoring NCT07662122, a Phase 2 "Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight." This study is open to adults with a BMI of 30 kg/m2 or more, or 27 kg/m2 or more with at least 1 weight-related health problem, aiming for 300 participants.
• For a less common condition, Yale University is sponsoring NCT07661342, the Phase 3 "DEPART Study at Yale," which is a randomized study to determine whether radiation therapy reduces the risk of progression or recurrence of Dupuytren's disease or contracture, with 158 participants.

Conditions and Interventions in Focus

The 15 new trials opening this month in Connecticut cover a range of health conditions. The most common conditions addressed by these new studies include:

• Overweight (2 trials)
• Migraine (2 trials)
• Chronic pain (2 trials)
• Obesity (2 trials)
• Healthy adult/participants/volunteer (5 trials combined)
• Dupuytren's contracture (1 trial)
• Low back pain (1 trial)

In terms of intervention types, drug trials lead the way, accounting for 13 of the new studies. Behavioral and radiation interventions each account for 1 new trial.

Connecticut's Research Footprint: Spreading Across the State

Connecticut's clinical research landscape is robust, with 1,236 clinical trials currently recruiting across 53 cities and 590 research sites statewide. This month, new research initiatives are notably distributed, ensuring opportunities are accessible beyond just the largest metropolitan areas. Cities welcoming new trials include:

• Hamden (4 new trials)
• New Haven (3 new trials)
• Waterbury (3 new trials)
• Stamford (2 new trials)
• Bridgeport (1 new trial)
• West Haven (1 new trial)
• Greenwich (1 new trial)

This geographic spread highlights a commitment to making cutting-edge research opportunities available to a broader population across Connecticut.

Opportunities for Healthy Volunteers and Diverse Participants

For individuals without a specific medical condition, there are significant opportunities to contribute to medical science. Of the 15 new trials launched this month, 5 are actively seeking healthy volunteers. Statewide, a total of 153 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials in Connecticut are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 1 includes children as participants, and 12 include older adults, ensuring that research benefits diverse age groups. Industry sponsors are driving the majority of new research efforts, with 13 new trials sponsored by pharmaceutical companies such as Eli Lilly and Company, Kallyope Inc., MODAG GmbH, Gasherbrum Bio, Inc., Pfizer, and AstraZeneca. The VA Office of Research and Development and other academic institutions also contribute to the state's vibrant research ecosystem.

As we move through June, the focus will remain on the ongoing enrollment in these significant trials and the exploration of new treatments, diagnostics, and preventive measures for a broad spectrum of health challenges across Connecticut.